ACM
ARQT icon

Aquatic Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Aquatic Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.26M Buy
86,130
+51,523
+149% +$1.2M 0.08% 332
2026
Q1 		$815K Sell
34,607
-26,005
-43% -$664K 0.02% 613
2025
Q4 		$1.76M Buy
+60,612
New +$1.55M 0.05% 407
2024
Q3 		– Sell
-26,500
Closed -$246K – 1140
2024
Q2 		$246K Buy
+26,500
New +$240K 0.01% 698

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Aquatic Capital Management's ARQT Position: Q2 2026 in Review

Aquatic Capital Management increased its Arcutis Biotherapeutics (ARQT) stake by 149% in Q2 2026, buying an estimated $1.2M and bringing the position to 86,130 shares worth $2.26M. The position accounts for 0.08% of the portfolio, ranked #332.

Aquatic Capital Management first reported a position in ARQT in Q2 2024 and has held it in 4 quarters since. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Aquatic Capital Management held 86,130 shares of Arcutis Biotherapeutics worth $2.26M as of Q2 2026.
  • Aquatic Capital Management bought 51,523 Arcutis Biotherapeutics shares in Q2 2026, an estimated $1.2M.
  • Arcutis Biotherapeutics made up 0.08% of Aquatic Capital Management's portfolio in Q2 2026, its #332 holding.
  • Aquatic Capital Management first reported a position in Arcutis Biotherapeutics in Q2 2024 and has held it in 4 quarters since.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Aquatic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.